Stock RGNX REGENXBIO INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages REGENXBIO Inc.

Equities

RGNX

US75901B1070

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-11 pm EDT 		5-day change 1st Jan Change
12.71 USD +18.34% Intraday chart for REGENXBIO Inc. +17.47% -29.19%
Jun. 24 Regenxbio Enrolling New Group for Phase 1/2 Duchenne Muscular Dystrophy Trial MT
Jun. 24 REGENXBIO Inc. Announces Expansion of Affinity Duchenne Trial to Include a New Cohort of Younger Patients CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Regenxbio Enrolling New Group for Phase 1/2 Duchenne Muscular Dystrophy Trial
REGENXBIO Inc. Announces Expansion of Affinity Duchenne Trial to Include a New Cohort of Younger Patients
Sarepta surges as investors cheer expanded use of gene therapy
Sarepta surges as investors cheer expanded use of gene therapy
Regenxbio Reports 'Successful' Meeting With FDA For RGX-121
REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II
REGENXBIO Inc. Announces Chief Executive Officer Changes
REGENXBIO Inc. Announces Management Changes
Regenxbio Names Curran Simpson President, CEO
REGENXBIO Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
REGENXBIO Inc. Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD
Regenxbio Insider Sold Shares Worth $365,220, According to a Recent SEC Filing
Regenxbio Plans to Sell $125 Million in Equity Offering
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday
Sector Update: Health Care
Regenxbio Reports Higher Microdystrophin Expression in Phase 1/2 Duchenne Study
REGENXBIO Inc. Announces New Interim Safety and Efficacy Data from Duchenne Trial
REGENXBIO Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
REGENXBIO Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Sector Update: Health Care Stocks Firmer Late Afternoon
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RGNX Stock
  4. News REGENXBIO Inc.
  5. Other languages